mounjaro tirzepatide beschikbaarheid nederland 2025 Company of the Year 2025: Eli Lilly – Among the heavyweights Mounjaro vanaf 1 juli 2025

In November 2023, Zepbounds manufacturer, Eli Lilly, noted that FDA approval was based on results from the phase 3 SURMOUNT-1 and SURMOUNT-2 clinical trials

Mean BMI reductions in SURMOUNT-1s highest-dose group reached approximately 5.5 to 6 points, moving many participants from the obese range into the overweight category and a subset out of the overweight category entirely

The non-negotiables: Supplements most Tirzepatide users should consider Some supplements aren't optional when you're on tirzepatidethey address fundamental needs that are nearly impossible to meet through reduced food intake alone

How It Enhances Your Journey : Supplements can support your weight loss efforts by addressing nutritional deficiencies and targeting metabolic function

How Orderly Meds compares to alternatives Context matters